Will These Patents Be the Key to Amarin's Success?

Investors have recently focused on the NCE status for Amarin's (Nasdaq: AMRN  ) triglyceride-lowering drug Vascepa and potential suitors for the company, but many might be overlooking a topic that is essential to the future of this biotech stock: patents.

A cascade of patents protecting Vascepa from generic competitors has been rolling in lately, and Amarin is keen on obtaining more IP for its flagship product. In this video, health-care analysts Max Macaluso and Brenton Flynn talk about the drug's latest patents, and discuss why they are so vital for Amarin today.

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air,  the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Max's premium research report. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2129540, ~/Articles/ArticleHandler.aspx, 10/2/2014 2:31:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement